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Treatment modeAbstract To fully define clinical efficacy of highly active antiretroviral therapy for AIDS, analyze
patients’ survival time and treatment mode after receiving treatment, and provide scientific theory
to guide improvement of antiviral therapy, this paper selected 3100 cases of patients diagnosed with
AIDS during April 2006 and April 2014 as object of this study. All patients were treated with highly
active antiretroviral therapy. The main analysis contents of this study include CD4 + T lymphocyte
count, viral load changes, incidence of opportunistic infections, specific cause of death and the like.
The results show that patients’ CD4 + T lymphocyte levels are significantly increased 3, 18, and
24 months after treatment, difference between the situation after and before receiving treatment,
P< 0.05, with statistically significant difference. Analyzed from effective inhibition of virus, effec-
tive inhibition rate is 72.58.0% (2250/3100). Main causes of death in patients is usually respiratory
failure. It thus can be concluded that highly active antiretroviral therapy for AIDS is with good clin-
ical effect, which can effectively improve survival time of patients. So it enjoys application value of
being widely used in clinical treatment of AIDS.
 2016 The Authors. Production and Hosting by Elsevier B.V. on behalf of King Saud University. This is
an open access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The AIDS is a infectious disease of great danger, which is
caused by HIV virus. HIV is a virus that can attack the body’simmune system (Figs. 1–3), which takes T lymphocytes, the
most important part in the body’s immune system, as the main
target, greatly destroy the cells, resulting in loss of human
immune function. Thus, the body is susceptible to infection
with various diseases, possibly leading to malignant tumors.
The mortality is relatively high.
Average incubation period of HIV in the human body is 8–
9 years. Before AIDS, patients can live and work for many
years without any symptoms. Once AIDS is developed,
patients will have a variety of clinical manifestations. Early
symptoms are like common cold, flu, with general fatigue,
weakness, loss of appetite, fever, etc. As the disease worsens,
Figure 2 HIV virus form.
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Figure 1 HIV virus structure.
Research on AIDS patients’ survival time 319symptoms increase in number, such as candida albican infec-
tion of skin and mucous membrane, appearance of herpes sim-
plex, herpes zoster, purple plague, blood blisters, and
congestion spots; later, visceral organs are gradually violated,
which leads to unexplained persistent fever up to 3–4 months;
also cough, shortness of breath, difficulty breathing, persistent
diarrhea, hemafecia, hepatosplenomegaly, malignancy and the
like will occur. Clinical symptoms are complex and changeful,
but each patient doesn’t have all above symptoms. In case of
violation of the lung, difficulty in breathing, chest pain, and
cough will occur; gastrointestinal violation can cause persistent
diarrhea, abdominal pain, weight loss and weakness; violations
of the nervous system and cardiovascular system can also be
caused. As AIDS will cause long-term consumption of
patients’ body organ function, most patients show systemic
organ failure at death. Many medical researchers all over the
world have done a lot of research in treatment of AIDS, but
so far specific drug that can cure AIDS has not yet been devel-
oped, and also, there exists no effective vaccines for preven-
tion. Due to its high risk and difficulty to cure, AIDS is
listed as one of communicable diseases of frontier health
surveillance. In recent years, highly active antiretroviral treat-
ment has been found in clinics to have a more favorable ther-
apeutic effect. Combination of several (usually three or four)
antiretroviral drugs is known as highly active antiretroviral
therapy (HAART). However, due to complexity of drug com-
binations and administration methods, as well as serious pos-
sible side effects, moreover, drug resistance of the virus for the
drugs, clinical studies suggest that risk and benefits of this type
of iatrotechnique for patients without symptoms should be
analyzed to choose therapeutic method, as antiretroviral drugs
of different types act on different stages of HIV life cycle (Yin
et al., 2015; Gulisaina et al., 2015; Liang, 2015). The paper
conducts sampling study of 3000 cases of AIDS patients, with
specific circumstances shown below.
2. Materials and methods
2.1. General information
The 3100 cases are randomly selected from AIDS patients trea-
ted in 2011 for investigation and analysis. All patients were
confirmed as anti-HIV positive, with minimum follow-up of
six months and maximum follow-up of 10 years. Among them,
there are 1818 cases of male, 1282 cases of female; patients
were aged 10–71 years, with average age at (38.9 ± 6.9) years;
transmission routes include intravenous drug addiction, sexual
transmission, blood transfusion transmission, single plasma
transmission, and unknown routes.
2.2. Treatment methods
In this study, used highly active antiretroviral therapy drugs
are provided free of charge, including nucleoside reverse tran-
scriptase inhibitor, non-nucleoside reverse transcriptase inhibi-
tor and protease inhibitor. Nucleoside reverse transcriptase
inhibitors include zidovudine (AZT, ZDV), lamivudine
(3TC), stavudine (D4T); non-nucleoside reverse transcriptase
inhibitors include nevirapine (NVP) and efavirenz (EFV),
and protease inhibitor is kaletra (LVP). The pharmaceutical
compositions selected by patients conform to state regulations:
320 R. Lv et al.AZT+ 3TC+ NVP (EFV); D4T + 3TC+NVP (EFV),
wherein, AZT + TC+NVP belongs to first-line drug use in
national regulation. Before patients’ antiviral therapy, when
hemoglobin <90 g/L, use D4T + 3TC+ NVP (EFV); when
there is NVP allergy, switch to EFV; in case of tuberculosis
infection and antituberculosis therapy, NVP is replaced by
EFV; in case of allergy to NVP and EFV, switch to LVP.
The specific treatment regimens used in the study process
include the following: AZT + 3TC+ EFV, D4T + 3TC
+NVP, D4T + 3TC+ EFV, AZT + 3TC+ LVP, LVP
+ TDF+ 3TC, EFV + TDF+ 3TC.
2.3. Analysis method
Follow-up time after treatment is 3, 6, and 12 months after
treatment starts, with one detection every six months after1 -
year of treatment.
2.4. Statistical method
The study uses SPSS19.0 for statistical analysis, with (n, %) to
denote count data to be tested with chi-square test. Mean
value ± mean is adopted to denote measurement data, to be
tested with t-value test. When P< 0.05, it indicates that differ-
ence is with statistical significance.3. Results
CD4 + T lymphocyte test results and regression analysis show
that after treatment, CD4 + T cell counts of all patients are
increased gradually, increasing from pre-treatment average of
230 * 106/L to 660 * 106/L at 12 months after treatment, dif-
ference between groups P< 0.05, statistically significant.
Research result of survival time of patients after highly
active antiretroviral therapy shows that, among 3000 patients
in this study, analysis is done based on patients’ mortality
and treatment data. Kaplan–Meier method is adopted to make
survival curve, and survival situation of patients who receive
antiretroviral therapy is analyzed with Cox regression analysis
method. Final results show that, with the passage of treatment
time, patients’ survival rate continuously drops. In the begin-
ning 1–3 months, patients’ survival situation is relatively good,
but from the beginning of third month, there appears a sharp
decline, with not big falling range from fifth to ninth month,
and continued decline by 10th month.
Highly active antiretroviral therapy (HAART) can effec-
tively inhibit viral replication in vivo in patients and promote
immune function recovery, change morbidity after HIV infec-
tion, and reduce various opportunistic infections and mortal-
ity, so as to prolong lives of patients and improve their
quality of life. Also, because of significant decline in amount
of virus in patients’ body, spread of HIV can be reduced,
thereby reducing new-onset infection rate. Overseas studies
have shown that HAART can make HIV spread in heterosex-
ual transmission reduced by 92–98%. As effect of HAART is
affected by many factors, such as patient compliance, individ-
ual differences, drug regimen, drug toxic and side effects,
beginning time of treatment, pre-treatment levels of plasma
viral load, etc., timely evaluation of patients’ survival time
after HAART and treatment effect, and understanding of fac-tors that affect survival time of patients and HAART effect are
very important and urgent.
4. Discussion and conclusion
Guangxi is one of China’s high-prevalence areas of AIDS,
ranking second in the country. As of December 31, 2011,
Guangxi has accumulatively reported 72,295 cases of HIV
infected persons and AIDS patients, including 44,316 cases
of HIV infected persons, 27,979 cases of AIDS patients and
18,418 cases of death. In 2011, a total of 14183 HIV infected
persons and patients were reported, with heterosexual trans-
mission ratio reaching 90.8%, which indicates that sexual
transmission continues to be the main route of transmission
in our region. Given the grim situation of AIDS epidemic in
Guangxi, how to use limited medical resources to treat HIV
infected persons and AIDS patients, so as to minimize morbid-
ity and mortality and reduce the spread of AIDS, has become
an important link of our region’s AIDS prevention and control
work. This research study is mainly aimed at survival time and
therapeutic effect of patients after highly active antiretroviral
therapy, which retrospectively and prospectively collected
information of about 3000 AIDS cases through integrated
information management system for AIDS prevention and
control, observed patients’ survival time, monitored viral load,
CD4 + T lymphocytes and detection clinical parameters of
patients, and evaluated HAART effect. The results demon-
strate obvious relationship between survival time of patients
and cycle length of treatment duration. With longer duration
of treatment, patients’ survival rate will be reduced accord-
ingly. In addition, this study demonstrates that the present
study is with significant treatment effect and good clinical
effect.
Antiretroviral drugs are substantially classified in accor-
dance with different times of drugs that inhibit life cycle of
retrovirus (Lv et al., 2015; Hu et al., 2015; Sun, 2015). There-
fore, antiretroviral drugs are generally classified as follows:
Enzyme inhibitor: Reverse transcriptase inhibitor (RTI)
targets at inhibiting virus DNA synthesis through inhibi-
tion of activity of reverse transcriptase.
Protease inhibitor (PI): It targets at assembly of inhibiting
virus through inhibition of activity of protease. HIV uses
protease to split the initial protein and assemble the final
new virions.
Fusion inhibitor: It prevents HIV from entering into and
infecting cell through fusion of cell membrane. Integrase
inhibits integration of inhibitory enzyme and is very impor-
tant for viral DNA’s fusion into infection cell.
Fixed-dose combination: Fixed-dose combination combi-
nes a variety of antiretroviral drugs to form a tablet.
In just 1.5 days, HIV virus can finish the process of entry
into the cell, replicating genetic material, assembling new virus
and releasing infection to other cells (Fu et al., 2014). HIV
virus lacks enzyme to correct errors in the process from
RNA to DNA reverse transcription. In such a short period,
high error rate results in quite rapid virus mutation, bringing
in high genetic mutation rate of HIV (Yu et al., 2014; Zhang
et al., 2010). Compared to parental virus, most variations have
no advantage, but some mutations inherit parental advantage,
Research on AIDS patients’ survival time 321so that the virus is easier to resist the body’s immune system
and antiretroviral drug prevention (Chen and Ju, 2012). The
higher activity of the virus, the stronger drug resistance to
antiretroviral drug. Therefore, combination therapy of
antiretroviral drugs is very important for suppression of HIV
viral replication and antiviral resistance.Acknowledgments
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